Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Homeobox protein aristaless-like 4 (ALX4) is a member of the aristaless-related class of paired-type homeodomain transcription factors expressed predominantly in the mesenchyme of developing bones, limb buds, craniofacial structures, hair, teeth, and mammary tissue. It binds DNA to regulate the expression of genes essential for embryonic patterning, particularly in the skull and limbs, by controlling cell proliferation, differentiation, and migration. Mutations in ALX4 result in congenital disorders such as enlarged parietal foramina-2 and frontonasal dysplasia type 2, manifesting as defects in cranial bone ossification, midface anomalies, polydactyly, alopecia, and hypogonadism. ALX4 does not currently serve as a therapeutic target for pharmacologic intervention; rather, its clinical relevance is primarily in genetic diagnosis and counseling for developmental syndromes associated with its mutations.
Not applicable (no known drugs directly target ALX4)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Homeobox protein aristaless-like 4 (ALX4).